Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

Collaboration with new pharma company paves the way for new NF treatments

SpringWorks Therapeutics, a Pfizer-conceived, mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, launched today with news of promising investigational therapies, including one for neurofibromatosis.  The Children’s Tumor Foundation is collaborating with this new company to connect the NF community with these much-needed therapies.

SpringWorks represents an innovative approach to drug development, with a business model designed to deliver both social and financial returns via partnerships with a variety of stakeholders, including scientists, biopharmaceutical partners, patient groups, funders and philanthropists. It is being launched with funding from Pfizer, Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, and LifeArc. SpringWorks Therapeutics also has rights to four clinical-stage experimental therapies from Pfizer.

One of those therapies is of benefit to patients with plexiform neurofibromatosis. SpringWorks Therapeutics is planning to initiate a Phase 3 program to establish safety and efficacy of its MEK 1/2 inhibitor (PD-0325901) in the NF1 population, in collaboration with the Children’s Tumor Foundation in order to enable the needs of the patient community.

MEK inhibitors have shown encouraging activity in reducing tumor size in clinical studies, a result of CTF’s investment in the NF Preclinical Consortium. The groundbreaking work of that consortium demonstrated that MEK inhibitors have significant impact on tumor size, and that work now informs the MEK studies that SpringWorks is moving forward.

Read the full press release here.

Read more at Bloomberg.

 

Close Menu